COMPASS Pathways plc (CMPS)

Market Cap	832.08M +119.0%
Revenue (ttm)	n/a
Net Income	-237.32M
EPS	-2.74
Shares Out	113.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,975,655
Open	7.33
Previous Close	7.44
Day's Range	6.99 - 7.49
52-Week Range	2.25 - 8.90
Beta	1.93
Analysts	Strong Buy
Price Target	18.71 (+155.25%)
Earnings Date	Feb 26, 2026

About CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 166
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS
• Website: https://compasspathways.com

Analyst Summary

According to 8 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $18.71, which is an increase of 155.25% from the latest price.

Price Target

$18.71

(155.25% upside)

Analyst Consensus: Strong Buy